» Articles » PMID: 34451801

Do Small Molecules Activate the TrkB Receptor in the Same Manner As BDNF? Limitations of Published TrkB Low Molecular Agonists and Screening for Novel TrkB Orthosteric Agonists

Abstract

TrkB is a tyrosine kinase receptor that is activated upon binding to brain-derived neurotrophic factor (BDNF). To date, the search for low-molecular-weight molecules mimicking BDNF's action has been unsuccessful. Several molecules exerting antidepressive effects in vivo, such as 7,8-DHF, have been suggested to be TrkB agonists. However, more recent publications question this hypothesis. In this study, we developed a set of experimental procedures including the evaluation of direct interactions, dimerization, downstream signaling, and cytoprotection in parallel with physicochemical and ADME methods to verify the pharmacology of 7,8-DHF and other potential reference compounds, and perform screening for novel TrkB agonists. 7,8 DHF bound to TrkB with K = 1.3 μM; however, we were not able to observe any other activity against the TrkB receptor in SN56 T48 and differentiated SH-SY5Y cell lines. Moreover, the pharmacokinetic and pharmacodynamic effects of 7,8-DHF at doses of 1 and 50 mg/kg were examined in mice after i.v and oral administration, respectively. The poor pharmacokinetic properties and lack of observed activation of TrkB-dependent signaling in the brain confirmed that 7,8-DHF is not a relevant tool for studying TrkB activation in vivo. The binding profile for 133 molecular targets revealed a significant lack of selectivity of 7,8-DHF, suggesting a distinct functional profile independent of interaction with TrkB. Additionally, a compound library was screened in search of novel low-molecular-weight orthosteric TrkB agonists; however, we were not able to identify reliable drug candidates. Our results suggest that published reference compounds including 7,8-DHF do not activate TrkB, consistent with canonical dogma, which indicates that the reported pharmacological activity of these compounds should be interpreted carefully in a broad functional context.

Citing Articles

The role of brain-derived neurotrophic factor and its recombinant pro-isoforms in depressive disorder: Open questions.

Rodrigues E, Fachin A, Marins M, Letieri F, Stabeli R, Beleboni R Biotechnol Notes. 2025; 5:137-139.

PMID: 39764065 PMC: 11701254. DOI: 10.1016/j.biotno.2024.09.001.


Selective, Intrinsically Fluorescent Trk Modulating Probes.

Pewklang T, Thompson T, Sefiani A, Geoffroy C, Kamkaew A, Burgess K ACS Chem Neurosci. 2024; .

PMID: 39356215 PMC: 11487604. DOI: 10.1021/acschemneuro.4c00290.


Positive Allosteric Modulators of Trk Receptors for the Treatment of Alzheimer's Disease.

Forsell P, Parrado Fernandez C, Nilsson B, Sandin J, Nordvall G, Segerdahl M Pharmaceuticals (Basel). 2024; 17(8).

PMID: 39204102 PMC: 11357672. DOI: 10.3390/ph17080997.


The Antidepressant Action of Fluoxetine Involves the Inhibition of in Cortical GABAergic Neurons through a TrkB-Dependent Pathway.

Aouci R, Fontaine A, Vion A, Belz L, Levi G, Narboux-Neme N Cells. 2024; 13(15.

PMID: 39120293 PMC: 11311550. DOI: 10.3390/cells13151262.


Decreasing the physical gap in the neural-electrode interface and related concepts to improve cochlear implant performance.

Vecchi J, Claussen A, Hansen M Front Neurosci. 2024; 18:1425226.

PMID: 39114486 PMC: 11303154. DOI: 10.3389/fnins.2024.1425226.


References
1.
Chang H, Wang Y, Tung C, Yeh C, Liu Y . 7,8-Dihydroxyflavone, a Tropomyosin-Kinase Related Receptor B Agonist, Produces Fast-Onset Antidepressant-Like Effects in Rats Exposed to Chronic Mild Stress. Psychiatry Investig. 2016; 13(5):531-540. PMC: 5067348. DOI: 10.4306/pi.2016.13.5.531. View

2.
Shen J, Ghai K, Sompol P, Liu X, Cao X, Iuvone P . N-acetyl serotonin derivatives as potent neuroprotectants for retinas. Proc Natl Acad Sci U S A. 2012; 109(9):3540-5. PMC: 3295250. DOI: 10.1073/pnas.1119201109. View

3.
Akhondzadeh S, Jafari S, Raisi F, Nasehi A, Ghoreishi A, Salehi B . Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety. 2009; 26(7):607-11. DOI: 10.1002/da.20589. View

4.
Ferguson J . SSRI Antidepressant Medications: Adverse Effects and Tolerability. Prim Care Companion J Clin Psychiatry. 2004; 3(1):22-27. PMC: 181155. DOI: 10.4088/pcc.v03n0105. View

5.
Massa S, Yang T, Xie Y, Shi J, Bilgen M, Joyce J . Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents. J Clin Invest. 2010; 120(5):1774-85. PMC: 2860903. DOI: 10.1172/JCI41356. View